Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (1180)	11/10/1999 11:15:00 AM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 1686

fwiw, a small update on Avonex. ----- Study: Biogen's Avonex Preserves Tissue In MS Patients 11/09/1999 Dow Jones News Service BUFFALO -(Dow Jones)- A study published in the journal "Neurology" indicates that Biogen Inc.'s (BGEN) Avonex drug is therapeutic to patients with relapsing or remitting forms of multiple sclerosis. In a press release Tuesday, Buffalo General Hospital said the journal article indicates that patients enrolled in a Phase III trial who were treated with Avonex experienced preservation of their brain tissue. The hospital said the discrepancy among patients treated with Avonex and those treated with a placebo was about 50%. The study also indicated that Avonex "significantly reduces" the rate of brain atrophy during the second year of treatment.